Lower complement C1q levels in first-episode psychosis and in schizophrenia
[Display omitted] •C1QA expression is reduced in prefrontal cortex tissue of individuals with schizophrenia.•C1QA brain co-expression networks do not exhibit genetic enrichment for schizophrenia independent of C4A.•Already during the first acute psychotic episode, cerebrospinal fluid C1qA protein le...
Gespeichert in:
Veröffentlicht in: | Brain, behavior, and immunity behavior, and immunity, 2024-03, Vol.117, p.313-319 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 319 |
---|---|
container_issue | |
container_start_page | 313 |
container_title | Brain, behavior, and immunity |
container_volume | 117 |
creator | Koskuvi, Marja Malwade, Susmita Gracias Lekander, Jessica Hörbeck, Elin Bruno, Sanna Holmen Larsson, Jessica Pelanis, Aurimantas Isgren, Anniella Goulding, Anneli Fatouros-Bergman, Helena Samudyata Schalling, Martin Piehl, Fredrik Erhardt, Sophie Landen, Mikael Cervenka, Simon Orhan, Funda Sellgren, Carl M. |
description | [Display omitted]
•C1QA expression is reduced in prefrontal cortex tissue of individuals with schizophrenia.•C1QA brain co-expression networks do not exhibit genetic enrichment for schizophrenia independent of C4A.•Already during the first acute psychotic episode, cerebrospinal fluid C1qA protein levels are reduced in schizophrenia.
Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10-05), while C1QA seeded co-expression networks displayed no enrichment for schizophrenia risk variants beyond C4A. We then used targeted liquid chromatography-mass spectrometry (LS-MS) to measure cerebrospinal fluid (CSF) levels of C1qA in 113 individuals with first-episode psychosis (FEP), among which 66 individuals was later diagnosed with schizophrenia, and 87 healthy controls. CSF concentrations of C1qA were lower in individuals diagnosed with FEP (P = 0.0001), also after removing subjects with a short-term prescription of an antipsychotic agent (P = 0.0005). We conclude that C1q mRNA and protein levels are lower in schizophrenia and that further experimental studies are needed to understand the functional implications. |
doi_str_mv | 10.1016/j.bbi.2024.01.219 |
format | Article |
fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_845467</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0889159124002319</els_id><sourcerecordid>2929129821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c609t-49df63825d2e8b78543d2751aff94d35308b90952d547b03481676ddb282aa743</originalsourceid><addsrcrecordid>eNqdks1u1DAUhS0EosPAA7BBWbIgwdc_iS1W1ZQ_MRIbYGsl8c2Mh0yc2kmr8vR4mGlh0y5Y2bK_7-jq6hDyEmgBFMq3u6JpXMEoEwWFgoF-RBZANc0ZcP2YLKhSOgep4Yw8i3FHKZUc1FNyxhWnoIVakC9rf40ha_1-7HGPw5St4DLr8Qr7mLkh61yIU46ji95iNsabduuji1k92MN3bLfulx-3AQdXPydPurqP-OJ0Lsn3D--_rT7l668fP6_O13lbUj3lQtuu5IpJy1A1lZKCW1ZJqLtOC8slp6rRVEtmpagayoWCsiqtbZhidV0JviT5MTde4zg3ZgxuX4cb42tnTk8_0w2NElKUVeL1vfwYvP0r3YrsdkH_4YKUUAlGywfn3MyjSU-b-aBwXgLliX9zL3_hfpwbHzZmno1kQv7BXx_xNMfljHEyexdb7Pt6QD9HwzTTwLRKZVgSOKJt8DEG7O6ygZpDlczOpCqZQ5UMBZOqlJxXp_i52aO9M_5ZzbsjkKqCVw6Dia3DoUXrAraTsd49EP8b7U_a8Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2929129821</pqid></control><display><type>article</type><title>Lower complement C1q levels in first-episode psychosis and in schizophrenia</title><source>SWEPUB Freely available online</source><source>Access via ScienceDirect (Elsevier)</source><creator>Koskuvi, Marja ; Malwade, Susmita ; Gracias Lekander, Jessica ; Hörbeck, Elin ; Bruno, Sanna ; Holmen Larsson, Jessica ; Pelanis, Aurimantas ; Isgren, Anniella ; Goulding, Anneli ; Fatouros-Bergman, Helena ; Samudyata ; Schalling, Martin ; Piehl, Fredrik ; Erhardt, Sophie ; Landen, Mikael ; Cervenka, Simon ; Orhan, Funda ; Sellgren, Carl M.</creator><creatorcontrib>Koskuvi, Marja ; Malwade, Susmita ; Gracias Lekander, Jessica ; Hörbeck, Elin ; Bruno, Sanna ; Holmen Larsson, Jessica ; Pelanis, Aurimantas ; Isgren, Anniella ; Goulding, Anneli ; Fatouros-Bergman, Helena ; Samudyata ; Schalling, Martin ; Piehl, Fredrik ; Erhardt, Sophie ; Landen, Mikael ; Cervenka, Simon ; Orhan, Funda ; Sellgren, Carl M.</creatorcontrib><description>[Display omitted]
•C1QA expression is reduced in prefrontal cortex tissue of individuals with schizophrenia.•C1QA brain co-expression networks do not exhibit genetic enrichment for schizophrenia independent of C4A.•Already during the first acute psychotic episode, cerebrospinal fluid C1qA protein levels are reduced in schizophrenia.
Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10-05), while C1QA seeded co-expression networks displayed no enrichment for schizophrenia risk variants beyond C4A. We then used targeted liquid chromatography-mass spectrometry (LS-MS) to measure cerebrospinal fluid (CSF) levels of C1qA in 113 individuals with first-episode psychosis (FEP), among which 66 individuals was later diagnosed with schizophrenia, and 87 healthy controls. CSF concentrations of C1qA were lower in individuals diagnosed with FEP (P = 0.0001), also after removing subjects with a short-term prescription of an antipsychotic agent (P = 0.0005). We conclude that C1q mRNA and protein levels are lower in schizophrenia and that further experimental studies are needed to understand the functional implications.</description><identifier>ISSN: 0889-1591</identifier><identifier>ISSN: 1090-2139</identifier><identifier>EISSN: 1090-2139</identifier><identifier>DOI: 10.1016/j.bbi.2024.01.219</identifier><identifier>PMID: 38301948</identifier><language>eng</language><publisher>Netherlands: Elsevier Inc</publisher><subject>Cerebrospinal fluid ; Complement C1q ; Complement C4 ; Medicin och hälsovetenskap ; Psychiatry ; Psykiatri ; Schizophrenia</subject><ispartof>Brain, behavior, and immunity, 2024-03, Vol.117, p.313-319</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c609t-49df63825d2e8b78543d2751aff94d35308b90952d547b03481676ddb282aa743</citedby><cites>FETCH-LOGICAL-c609t-49df63825d2e8b78543d2751aff94d35308b90952d547b03481676ddb282aa743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbi.2024.01.219$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>230,315,554,782,786,887,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38301948$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-524503$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttps://gup.ub.gu.se/publication/336103$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:155174206$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:238301948$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Koskuvi, Marja</creatorcontrib><creatorcontrib>Malwade, Susmita</creatorcontrib><creatorcontrib>Gracias Lekander, Jessica</creatorcontrib><creatorcontrib>Hörbeck, Elin</creatorcontrib><creatorcontrib>Bruno, Sanna</creatorcontrib><creatorcontrib>Holmen Larsson, Jessica</creatorcontrib><creatorcontrib>Pelanis, Aurimantas</creatorcontrib><creatorcontrib>Isgren, Anniella</creatorcontrib><creatorcontrib>Goulding, Anneli</creatorcontrib><creatorcontrib>Fatouros-Bergman, Helena</creatorcontrib><creatorcontrib>Samudyata</creatorcontrib><creatorcontrib>Schalling, Martin</creatorcontrib><creatorcontrib>Piehl, Fredrik</creatorcontrib><creatorcontrib>Erhardt, Sophie</creatorcontrib><creatorcontrib>Landen, Mikael</creatorcontrib><creatorcontrib>Cervenka, Simon</creatorcontrib><creatorcontrib>Orhan, Funda</creatorcontrib><creatorcontrib>Sellgren, Carl M.</creatorcontrib><title>Lower complement C1q levels in first-episode psychosis and in schizophrenia</title><title>Brain, behavior, and immunity</title><addtitle>Brain Behav Immun</addtitle><description>[Display omitted]
•C1QA expression is reduced in prefrontal cortex tissue of individuals with schizophrenia.•C1QA brain co-expression networks do not exhibit genetic enrichment for schizophrenia independent of C4A.•Already during the first acute psychotic episode, cerebrospinal fluid C1qA protein levels are reduced in schizophrenia.
Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10-05), while C1QA seeded co-expression networks displayed no enrichment for schizophrenia risk variants beyond C4A. We then used targeted liquid chromatography-mass spectrometry (LS-MS) to measure cerebrospinal fluid (CSF) levels of C1qA in 113 individuals with first-episode psychosis (FEP), among which 66 individuals was later diagnosed with schizophrenia, and 87 healthy controls. CSF concentrations of C1qA were lower in individuals diagnosed with FEP (P = 0.0001), also after removing subjects with a short-term prescription of an antipsychotic agent (P = 0.0005). We conclude that C1q mRNA and protein levels are lower in schizophrenia and that further experimental studies are needed to understand the functional implications.</description><subject>Cerebrospinal fluid</subject><subject>Complement C1q</subject><subject>Complement C4</subject><subject>Medicin och hälsovetenskap</subject><subject>Psychiatry</subject><subject>Psykiatri</subject><subject>Schizophrenia</subject><issn>0889-1591</issn><issn>1090-2139</issn><issn>1090-2139</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>D8T</sourceid><recordid>eNqdks1u1DAUhS0EosPAA7BBWbIgwdc_iS1W1ZQ_MRIbYGsl8c2Mh0yc2kmr8vR4mGlh0y5Y2bK_7-jq6hDyEmgBFMq3u6JpXMEoEwWFgoF-RBZANc0ZcP2YLKhSOgep4Yw8i3FHKZUc1FNyxhWnoIVakC9rf40ha_1-7HGPw5St4DLr8Qr7mLkh61yIU46ji95iNsabduuji1k92MN3bLfulx-3AQdXPydPurqP-OJ0Lsn3D--_rT7l668fP6_O13lbUj3lQtuu5IpJy1A1lZKCW1ZJqLtOC8slp6rRVEtmpagayoWCsiqtbZhidV0JviT5MTde4zg3ZgxuX4cb42tnTk8_0w2NElKUVeL1vfwYvP0r3YrsdkH_4YKUUAlGywfn3MyjSU-b-aBwXgLliX9zL3_hfpwbHzZmno1kQv7BXx_xNMfljHEyexdb7Pt6QD9HwzTTwLRKZVgSOKJt8DEG7O6ygZpDlczOpCqZQ5UMBZOqlJxXp_i52aO9M_5ZzbsjkKqCVw6Dia3DoUXrAraTsd49EP8b7U_a8Q</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Koskuvi, Marja</creator><creator>Malwade, Susmita</creator><creator>Gracias Lekander, Jessica</creator><creator>Hörbeck, Elin</creator><creator>Bruno, Sanna</creator><creator>Holmen Larsson, Jessica</creator><creator>Pelanis, Aurimantas</creator><creator>Isgren, Anniella</creator><creator>Goulding, Anneli</creator><creator>Fatouros-Bergman, Helena</creator><creator>Samudyata</creator><creator>Schalling, Martin</creator><creator>Piehl, Fredrik</creator><creator>Erhardt, Sophie</creator><creator>Landen, Mikael</creator><creator>Cervenka, Simon</creator><creator>Orhan, Funda</creator><creator>Sellgren, Carl M.</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ACNBI</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DF2</scope><scope>ZZAVC</scope><scope>F1U</scope></search><sort><creationdate>20240301</creationdate><title>Lower complement C1q levels in first-episode psychosis and in schizophrenia</title><author>Koskuvi, Marja ; Malwade, Susmita ; Gracias Lekander, Jessica ; Hörbeck, Elin ; Bruno, Sanna ; Holmen Larsson, Jessica ; Pelanis, Aurimantas ; Isgren, Anniella ; Goulding, Anneli ; Fatouros-Bergman, Helena ; Samudyata ; Schalling, Martin ; Piehl, Fredrik ; Erhardt, Sophie ; Landen, Mikael ; Cervenka, Simon ; Orhan, Funda ; Sellgren, Carl M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c609t-49df63825d2e8b78543d2751aff94d35308b90952d547b03481676ddb282aa743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cerebrospinal fluid</topic><topic>Complement C1q</topic><topic>Complement C4</topic><topic>Medicin och hälsovetenskap</topic><topic>Psychiatry</topic><topic>Psykiatri</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koskuvi, Marja</creatorcontrib><creatorcontrib>Malwade, Susmita</creatorcontrib><creatorcontrib>Gracias Lekander, Jessica</creatorcontrib><creatorcontrib>Hörbeck, Elin</creatorcontrib><creatorcontrib>Bruno, Sanna</creatorcontrib><creatorcontrib>Holmen Larsson, Jessica</creatorcontrib><creatorcontrib>Pelanis, Aurimantas</creatorcontrib><creatorcontrib>Isgren, Anniella</creatorcontrib><creatorcontrib>Goulding, Anneli</creatorcontrib><creatorcontrib>Fatouros-Bergman, Helena</creatorcontrib><creatorcontrib>Samudyata</creatorcontrib><creatorcontrib>Schalling, Martin</creatorcontrib><creatorcontrib>Piehl, Fredrik</creatorcontrib><creatorcontrib>Erhardt, Sophie</creatorcontrib><creatorcontrib>Landen, Mikael</creatorcontrib><creatorcontrib>Cervenka, Simon</creatorcontrib><creatorcontrib>Orhan, Funda</creatorcontrib><creatorcontrib>Sellgren, Carl M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SWEPUB Uppsala universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Uppsala universitet</collection><collection>SwePub Articles full text</collection><collection>SWEPUB Göteborgs universitet</collection><jtitle>Brain, behavior, and immunity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koskuvi, Marja</au><au>Malwade, Susmita</au><au>Gracias Lekander, Jessica</au><au>Hörbeck, Elin</au><au>Bruno, Sanna</au><au>Holmen Larsson, Jessica</au><au>Pelanis, Aurimantas</au><au>Isgren, Anniella</au><au>Goulding, Anneli</au><au>Fatouros-Bergman, Helena</au><au>Samudyata</au><au>Schalling, Martin</au><au>Piehl, Fredrik</au><au>Erhardt, Sophie</au><au>Landen, Mikael</au><au>Cervenka, Simon</au><au>Orhan, Funda</au><au>Sellgren, Carl M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lower complement C1q levels in first-episode psychosis and in schizophrenia</atitle><jtitle>Brain, behavior, and immunity</jtitle><addtitle>Brain Behav Immun</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>117</volume><spage>313</spage><epage>319</epage><pages>313-319</pages><issn>0889-1591</issn><issn>1090-2139</issn><eissn>1090-2139</eissn><abstract>[Display omitted]
•C1QA expression is reduced in prefrontal cortex tissue of individuals with schizophrenia.•C1QA brain co-expression networks do not exhibit genetic enrichment for schizophrenia independent of C4A.•Already during the first acute psychotic episode, cerebrospinal fluid C1qA protein levels are reduced in schizophrenia.
Recent evidence has implicated complement component (C) 4A in excessive elimination of synapses in schizophrenia. C4A is believed to contribute to physiological synapse removal through signaling within the C1q initiated classical activation axis of the complement system. So far, a potential involvement of C1q in the pathophysiology of schizophrenia remains unclear. In this study, we first utilized large-scale gene expression datasets (n = 586 patients with schizophrenia and n = 986 controls) to observe lower C1QA mRNA expression in prefrontal cortex tissue of individuals with schizophrenia (P = 4.8x10-05), while C1QA seeded co-expression networks displayed no enrichment for schizophrenia risk variants beyond C4A. We then used targeted liquid chromatography-mass spectrometry (LS-MS) to measure cerebrospinal fluid (CSF) levels of C1qA in 113 individuals with first-episode psychosis (FEP), among which 66 individuals was later diagnosed with schizophrenia, and 87 healthy controls. CSF concentrations of C1qA were lower in individuals diagnosed with FEP (P = 0.0001), also after removing subjects with a short-term prescription of an antipsychotic agent (P = 0.0005). We conclude that C1q mRNA and protein levels are lower in schizophrenia and that further experimental studies are needed to understand the functional implications.</abstract><cop>Netherlands</cop><pub>Elsevier Inc</pub><pmid>38301948</pmid><doi>10.1016/j.bbi.2024.01.219</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0889-1591 |
ispartof | Brain, behavior, and immunity, 2024-03, Vol.117, p.313-319 |
issn | 0889-1591 1090-2139 1090-2139 |
language | eng |
recordid | cdi_swepub_primary_oai_swepub_ki_se_845467 |
source | SWEPUB Freely available online; Access via ScienceDirect (Elsevier) |
subjects | Cerebrospinal fluid Complement C1q Complement C4 Medicin och hälsovetenskap Psychiatry Psykiatri Schizophrenia |
title | Lower complement C1q levels in first-episode psychosis and in schizophrenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T19%3A52%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lower%20complement%20C1q%20levels%20in%20first-episode%20psychosis%20and%20in%20schizophrenia&rft.jtitle=Brain,%20behavior,%20and%20immunity&rft.au=Koskuvi,%20Marja&rft.date=2024-03-01&rft.volume=117&rft.spage=313&rft.epage=319&rft.pages=313-319&rft.issn=0889-1591&rft.eissn=1090-2139&rft_id=info:doi/10.1016/j.bbi.2024.01.219&rft_dat=%3Cproquest_swepu%3E2929129821%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2929129821&rft_id=info:pmid/38301948&rft_els_id=S0889159124002319&rfr_iscdi=true |